GO:0070373 negative regulation of ERK1 and ERK2 cascade: Signaling Brake, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070373 describes any process that stops, prevents, or reduces the frequency, rate, or extent of signal transduction mediated by the ERK1 and ERK2 cascade.
• The ERK1/2 cascade is a central MAPK pathway controlling proliferation, differentiation, and survival, and its negative regulation is essential to prevent excessive signaling.
• Negative regulation occurs at multiple levels, including receptor desensitization, RasGAP-mediated hydrolysis of Ras-GTP, MAPK phosphatase (DUSP) dephosphorylation, and scaffolding-protein sequestration.
• Dysregulated negative regulation of ERK1/2 is implicated in cancer, where loss of feedback can drive tumorigenesis, and in other diseases such as melanoma and adrenal carcinoma [1,7].
• Key negative regulators include DUSP family phosphatases, SPRY proteins, RasGAPs such as NF1, and the RasGPR2-mediated feedback loop.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of negative regulators of ERK1/2 signaling in disease contexts [1,3].
Description
The ERK1 and ERK2 cascade is a highly conserved mitogen-activated protein kinase (MAPK) signaling module that transmits signals from cell surface receptors to transcription factors, thereby controlling fundamental cellular decisions such as proliferation, differentiation, and survival. Because sustained or aberrant ERK1/2 activity can drive oncogenesis and other pathologies, cells have evolved multiple layers of negative regulation to keep this pathway in check. GO:0070373, negative regulation of ERK1 and ERK2 cascade, captures the biological processes that attenuate or terminate ERK1/2 signaling. Understanding these brakes is critical for researchers studying signal transduction, cancer biology, and therapeutic resistance, as loss of negative regulation often contributes to disease [1,3].
negative regulation of ERK1 and ERK2 cascade At A Glance
| GO ID | GO:0070373 |
|---|---|
| GO term | negative regulation of ERK1 and ERK2 cascade |
| Ontology | biological_process |
| Synonym | negative regulation of ERK1/2 cascade; inhibition of ERK1 and ERK2 cascade; downregulation of ERK1 and ERK2 cascade; negative regulation of MAPK1 cascade; negative regulation of MAPK3 cascade |
| Major function | Attenuation or termination of signal transduction through the ERK1 and ERK2 MAPK cascade |
| Key regulators | DUSP phosphatases, SPRY proteins, RasGAPs (e.g., NF1), RasGPR2, and other feedback inhibitors |
| Associated diseases | Cancer, melanoma, adrenal carcinoma, and other conditions driven by hyperactive ERK1/2 signaling [1,7] |
| Research methods | CRISPR knockout/knock-in, RNA-seq, phospho-proteomics, live-cell imaging, and biochemical assays [1,3] |
What Is GO:0070373?
GO:0070373 is a Gene Ontology biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of signal transduction mediated by the ERK1 and ERK2 cascade. In other words, it encompasses all molecular events that dampen or shut down the ERK1/2 MAPK pathway, from receptor-level desensitization to phosphatase-mediated inactivation of ERK1/2 itself [1,5].
Why Is negative regulation of ERK1 and ERK2 cascade Important in Cell Biology?
Negative regulation of the ERK1/2 cascade is essential for maintaining cellular homeostasis and preventing uncontrolled proliferation. Many oncogenic mutations, such as those in RAS or BRAF, disrupt negative feedback loops, leading to sustained ERK1/2 activation that drives tumor growth and therapeutic resistance [1,3]. Conversely, excessive negative regulation can contribute to developmental disorders and impaired tissue repair. Therefore, understanding the mechanisms of GO:0070373 is crucial for identifying therapeutic targets and biomarkers in cancer and other diseases [1,7].
• Prevents sustained ERK1/2 signaling that would otherwise lead to oncogenic transformation.
• Shapes the duration and amplitude of ERK1/2 signals, which determine cell fate decisions such as proliferation versus differentiation.
• Loss of negative regulators like DUSPs or SPRY proteins is associated with various cancers.
• Feedback inhibition by RasGPR2 phosphorylation provides a rapid brake on ERK1/2 activation.
• Negative regulation is exploited by pathogens and contributes to inflammatory responses through TRAF-mediated pathways.
• Dysregulation of ERK1/2 negative feedback is linked to melanoma and adrenal carcinoma progression.
• Targeting negative regulators can sensitize tumors to MEK inhibitors.
• Understanding negative regulation aids in designing combination therapies that overcome drug resistance.
• It is critical for normal development, as evidenced by developmental defects in mice lacking negative regulators.
• Provides a paradigm for studying signal transduction dynamics in systems biology.
What Happens During negative regulation of ERK1 and ERK2 cascade?
Receptor-Level Desensitization and Feedback
In simple terms: The cell turns down the signal at the receptor before it even gets inside.
Negative regulation of ERK1/2 signaling often begins at the receptor level, where ligand-bound receptors are internalized, degraded, or desensitized by phosphorylation. This reduces the upstream input into the cascade, thereby limiting ERK1/2 activation.
RasGAP-Mediated Inactivation of Ras
In simple terms: A helper protein switches Ras off by helping it hydrolyze its activating molecule.
Ras proteins are active when bound to GTP, and their inactivation is catalyzed by Ras GTPase-activating proteins (RasGAPs) such as NF1. By accelerating GTP hydrolysis, RasGAPs terminate the signal from Ras to Raf, thereby negatively regulating the ERK1/2 cascade.
Feedback Phosphorylation of RasGPR2
In simple terms: ERK itself can trigger a brake by modifying a protein that dampens the pathway.
A negative-feedback loop mediated by RasGPR2 phosphorylation has been described, in which activated ERK1/2 phosphorylates RasGPR2, enhancing its ability to inhibit Ras and thus reducing further ERK1/2 activation.
Dephosphorylation by MAPK Phosphatases (DUSPs)
In simple terms: Enzymes called phosphatases remove phosphate groups from ERK, turning it off.
Dual-specificity phosphatases (DUSPs), also known as MAPK phosphatases, dephosphorylate the threonine and tyrosine residues in the activation loop of ERK1/2, directly inactivating the kinases. This is a major mechanism for terminating ERK1/2 signaling.
Sequestration by Scaffold Proteins
In simple terms: Scaffold proteins hold onto ERK and keep it away from its targets.
Scaffold proteins such as KSR and MP1 can sequester ERK1/2 in the cytoplasm, preventing nuclear translocation and phosphorylation of nuclear substrates, thereby negatively regulating the cascade.
Key Genes Involved in GO:0070373 negative regulation of ERK1 and ERK2 cascade
The following genes and proteins are key players in the negative regulation of the ERK1 and ERK2 cascade, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DUSP1 | Dephosphorylates ERK1/2 to terminate signaling | Frequently downregulated in cancers; target for restoring negative regulation |
| DUSP6 | Cytoplasmic phosphatase that specifically inactivates ERK1/2 | Feedback regulator; loss linked to tumor progression |
| SPRY2 | Inhibits Ras-Raf interaction and receptor signaling | Tumor suppressor; often silenced in cancer |
| NF1 | RasGAP that inactivates Ras | Loss-of-function mutations cause neurofibromatosis and cancers |
| RasGPR2 | Mediates feedback phosphorylation by ERK to inhibit Ras | Component of negative feedback loop |
| MAPK1 (ERK2) | Effector kinase of the cascade | Subject to negative regulation; mutations affect signaling |
| MAPK3 (ERK1) | Effector kinase of the cascade | Subject to negative regulation; mutations affect signaling |
| TRAF proteins | Mediate inflammatory signaling that can intersect with ERK1/2 | Role in negative regulation of inflammatory responses |
| VDR | Modulates MAPK ERK1/2 in breast cancer cells | Potential target in breast cancer |
| ETS transcription factors | Downstream targets of ERK1/2; feedback regulation | Therapeutic targets in cancers with ERK1/2 dysregulation |
| NF-M | Neurofilament substrate of ERK1/2 | Phosphorylation by ERK1/2 affects neuronal cytoskeleton |
| Calcineurin | Reverses negative feedback to increase ERK1/2 activation | Modulates glucose signaling |
| Mitotane | Drug that affects ERK1/2 signaling in adrenal carcinoma | Therapeutic agent; response linked to ERK1/2 status |
| BRAF | Upstream kinase in ERK1/2 cascade | Mutations disrupt negative feedback, driving melanoma |
| RAS | Upstream GTPase in ERK1/2 cascade | Mutations impair negative regulation, leading to cancer |
| MEK1/2 | Upstream kinases of ERK1/2 | Targets of inhibitors; feedback regulation important |
| KSR | Scaffold protein that can sequester ERK1/2 | Modulates pathway output |
| MP1 | Scaffold protein that binds ERK1/2 | Affects subcellular localization and activity |
How Is negative regulation of ERK1 and ERK2 cascade Regulated?
The negative regulation of ERK1/2 cascade is itself tightly regulated by feedback loops and cross-talk with other pathways. For example, calcineurin increases glucose activation of ERK1/2 by reversing negative feedback, indicating that phosphatases can modulate the brakes on the pathway. Additionally, TRAF proteins mediate inflammatory responses that can influence ERK1/2 negative regulation. These regulatory interactions ensure that ERK1/2 signaling is dynamic and context-dependent.
negative regulation of ERK1 and ERK2 cascade and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DUSP1 | Cancer (various) | Knockout and overexpression in cancer cell lines |
| SPRY2 | Cancer (various) | Knockout and rescue experiments |
| NF1 | Neurofibromatosis, cancer | Knockout mouse models and patient-derived cells |
| BRAF | Melanoma | Point mutation knock-in (V600E) in melanoma cell lines |
| RasGPR2 | Feedback regulation in cancer | Phospho-mutant knock-in and knockout |
Cancer
Loss of negative regulation of ERK1/2 is a hallmark of many cancers. Mutations in RAS or BRAF impair feedback inhibition, leading to constitutive ERK1/2 activation that drives proliferation and survival. Downregulation of DUSP phosphatases or SPRY proteins further exacerbates signaling. Targeting these negative regulators is a promising therapeutic strategy.
Melanoma and Adrenal Carcinoma
In melanoma and adrenal carcinoma, dysregulated ERK1/2 signaling contributes to tumor growth and resistance to therapy. Mitotane treatment affects ERK1/2 phosphorylation in adrenal carcinoma and melanoma cells, highlighting the clinical relevance of negative regulation.
Inflammatory Diseases
TRAF-mediated inflammatory responses intersect with ERK1/2 negative regulation, and dysregulation can lead to chronic inflammation. Understanding these interactions may reveal new anti-inflammatory targets.
Neurological Disorders
ERK1/2 phosphorylates neurofilament NF-M, and negative regulation of this cascade is important for neuronal cytoskeleton dynamics. Impaired negative regulation may contribute to neurodegeneration.
From negative regulation of ERK1 and ERK2 cascade-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of DUSP1 increase ERK1/2 activity? | DUSP1 knockout cell line |
| Does RasGPR2 phosphorylation mediate feedback? | RasGPR2 phospho-mutant knock-in |
| Can overexpression of SPRY2 inhibit tumor growth? | SPRY2 overexpression in cancer cells |
| Does NF1 mutation affect ERK1/2 negative regulation? | NF1 knockout or point mutation |
| How does BRAF V600E alter feedback? | BRAF V600E knock-in melanoma cells |
| Does calcineurin modulate ERK1/2 negative feedback? | Calcineurin knockout or overexpression |
How to Study the negative regulation of ERK1 and ERK2 cascade Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phospho-proteomics | Phosphorylation status of ERK1/2 and substrates | Identifying feedback and resistance |
| RNA-seq | Gene expression changes | Transcriptional feedback analysis |
| Live-cell imaging | Real-time ERK1/2 activity dynamics | Temporal regulation studies |
| CRISPR knockout screening | Loss-of-function phenotypes | Discovery of negative regulators |
| Western blot | Protein levels and phosphorylation | Validation of specific regulators |
| Co-immunoprecipitation | Protein-protein interactions | Scaffold and phosphatase interactions |
| Kinase activity assay | ERK1/2 catalytic activity | Direct measurement of negative regulation |
| Flow cytometry | Cell population signaling heterogeneity | Single-cell analysis |
Phospho-Proteomics
Phospho-proteomics allows global quantification of ERK1/2 phosphorylation and its downstream targets, providing a snapshot of negative regulation status. This method is useful for identifying feedback loops and resistance mechanisms.
RNA-seq and Transcriptomics
RNA-seq can reveal changes in expression of negative regulators such as DUSPs and SPRY proteins upon pathway activation or inhibition. It helps identify transcriptional feedback programs.
Live-Cell Imaging
Live-cell imaging with fluorescently tagged ERK1/2 or biosensors enables real-time monitoring of signaling dynamics and the impact of negative regulators. This is critical for understanding temporal control.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify novel negative regulators of the ERK1/2 cascade. Such screens are powerful for discovering therapeutic targets.
How CRISPR Can Be Used to Study GO:0070373 negative regulation of ERK1 and ERK2 cascade
Knockout
CRISPR knockout of negative regulators such as DUSP1 or SPRY2 can lead to hyperactivation of ERK1/2, providing a model to study loss of negative regulation in cancer. These models are valuable for testing targeted therapies.
Point Mutation
Point mutations in genes like BRAF (V600E) or RasGPR2 phosphorylation sites can be introduced using CRISPR to dissect their impact on negative feedback [1,5]. Such models mimic patient-specific mutations.
Knock-in
Knock-in of tagged ERK1/2 or negative regulators allows live-cell imaging and biochemical tracking of signaling dynamics. This approach helps visualize the spatiotemporal control of negative regulation.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can be used to overexpress negative regulators like DUSP6 or SPRY2, testing their ability to suppress ERK1/2 signaling and tumor growth. This is useful for validating tumor suppressor functions.
How EDITGENE Supports negative regulation of ERK1 and ERK2 cascade Research
Researchers studying negative regulation of ERK1 and ERK2 cascade-related genes often need to determine whether a candidate gene is causally involved in dampening the pathway or whether its manipulation alters disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such functional studies with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of ERK1 and ERK2 cascade research.
Frequently Asked Questions About negative regulation of ERK1 and ERK2 cascade
What is GO:0070373?
GO:0070373 is the Gene Ontology term for negative regulation of ERK1 and ERK2 cascade, describing any process that stops, prevents, or reduces signal transduction through the ERK1/2 MAPK pathway.
What genes are involved in negative regulation of ERK1 and ERK2 cascade?
Key genes include DUSP1, DUSP6, SPRY2, NF1, RasGPR2, and others that encode phosphatases, scaffold proteins, and GTPase-activating proteins [1,5].
Why is negative regulation of ERK1/2 important in cancer?
Loss of negative regulation leads to sustained ERK1/2 activation, driving proliferation and survival in many cancers, and contributes to resistance to targeted therapies [1,3].
How does RasGPR2 mediate negative feedback?
Activated ERK1/2 phosphorylates RasGPR2, which enhances its inhibition of Ras, thereby reducing further ERK1/2 activation.
What are DUSP phosphatases?
DUSPs are dual-specificity phosphatases that dephosphorylate ERK1/2, directly inactivating the kinases and terminating the signal.
Can CRISPR be used to study negative regulation of ERK1/2?
Yes, CRISPR knockout, knock-in, and overexpression models allow precise manipulation of negative regulators to study their function and impact on signaling.
What diseases are linked to dysregulated ERK1/2 negative regulation?
Cancer, melanoma, adrenal carcinoma, inflammatory diseases, and neurological disorders have been linked to altered negative regulation [1,4,6,7].
How does calcineurin affect ERK1/2 negative feedback?
Calcineurin can reverse negative feedback to increase glucose activation of ERK1/2, modulating the pathway's sensitivity.
What methods are used to study negative regulation of ERK1/2?
Phospho-proteomics, RNA-seq, live-cell imaging, and CRISPR screens are commonly used.
What is the role of TRAF proteins in ERK1/2 regulation?
TRAF proteins mediate inflammatory responses that intersect with ERK1/2 signaling and its negative regulation.
Conclusion
Negative regulation of the ERK1 and ERK2 cascade (GO:0070373) is a critical control mechanism that prevents excessive MAPK signaling and maintains cellular homeostasis. Its dysregulation is implicated in cancer and other diseases, making it a rich area for therapeutic targeting [1,3]. Advances in CRISPR-based models and multi-omics approaches continue to unravel the complex feedback networks that govern ERK1/2 activity [1,5].
References
- 1. Deschênes-Simard X et al.. 2014. ERKs in cancer: friends or foes?. Cancer Res 74(2):412-9 PMID: 24408923
- 2. Cordes T et al.. 2006. Modulation of MAPK ERK1 and ERK2 in VDR-positive and -negative breast cancer cell lines.. Anticancer Res 26(4A):2749-53 PMID: 16886687
- 3. Tetsu O et al.. 2017. ETS-targeted therapy: can it substitute for MEK inhibitors?. Clin Transl Med 6(1):16 PMID: 28474232
- 4. Dhillon B et al.. 2019. The Evolving Role of TRAFs in Mediating Inflammatory Responses.. Front Immunol 10:104 PMID: 30778351
- 5. Ren J et al.. 2016. A negative-feedback loop regulating ERK1/2 activation and mediated by RasGPR2 phosphorylation.. Biochem Biophys Res Commun 474(1):193-198 PMID: 27107697
- 6. Li BS et al.. 1999. Activation of mitogen-activated protein kinases (Erk1 and Erk2) cascade results in phosphorylation of NF-M tail domains in transfected NIH 3T3 cells.. Eur J Biochem 262(1):211-7 PMID: 10231383
- 7. Stelcer E et al.. 2022. Biological response of adrenal carcinoma and melanoma cells to mitotane treatment.. Oncol Lett 23(4):120 PMID: 35261634
- 8. Duan L et al.. 2010. Calcineurin increases glucose activation of ERK1/2 by reversing negative feedback.. Proc Natl Acad Sci U S A 107(51):22314-9 PMID: 21135229
